Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 18781882.
- Also identified by DOI 10.1086/592116 and PMC identifier 5909814.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.
Medical subject headings
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Azetidines
- Cholesterol, LDL
- HIV Infections
- Hypercholesterolemia